Hammami A, Arlet G, Ben Redjeb S, Grimont F, Ben Hassen A, Rekik A, Philippon A
Faculté de Médecine, Laboratoire de Bactériologie, Sfax, Tunisia.
Eur J Clin Microbiol Infect Dis. 1991 Aug;10(8):641-6. doi: 10.1007/BF01975816.
In a Tunisian hospital 27 babies, including 12 who were premature, in a single intensive care unit suffered acute gastroenteritis in the period from January to May 1988. The mean age at the onset of gastroenteritis was 8.4 days; nine babies died. Salmonella wien was isolated from stools (all babies) and blood (4 babies). It was also isolated from the stools of one nurse and from a mattress. Twelve of the babies had received cefotaxime, which was successfully replaced by oral colimycin. The outbreak was stopped by the implementation of infection control measures. All isolates of Salmonella wien were of the same biotype, and had the same antibiotic resistance pattern (third generation cephalosporins, monobactams, aminoglycosides, chloramphenicol, trimethoprim and sulphonamides) and plasmid DNA restriction pattern. The isolates were all susceptible to a combination of cefotaxime and clavulanic acid (a beta-lactamase inhibitor), which displayed synergy, suggesting the presence of a beta-lactamase (geometric mean MICs 11.24 micrograms/ml for cefotaxime alone and 0.24 micrograms/ml in combination with 0.1 micrograms/ml potassium clavulanate). All isolates produced TEM-1 and SHV-2 beta-lactamase which was not transferable to Escherichia coli by conjugation. The presence of the SHV-2 enzyme in Salmonella wien may allow it to adapt to newer beta-lactams which is a cause for concern in this hospital.
1988年1月至5月期间,突尼斯一家医院的一个重症监护病房里,27名婴儿患上了急性肠胃炎,其中包括12名早产儿。肠胃炎发病时的平均年龄为8.4天;9名婴儿死亡。从所有婴儿的粪便以及4名婴儿的血液中分离出了维也纳沙门氏菌。还从一名护士的粪便和一张床垫上分离出了该病菌。12名婴儿接受过头孢噻肟治疗,后成功改用口服黏菌素。通过实施感染控制措施,疫情得到了控制。所有维也纳沙门氏菌分离株都属于同一生物型,具有相同的抗生素耐药模式(对第三代头孢菌素、单环β-内酰胺类、氨基糖苷类、氯霉素、甲氧苄啶和磺胺类耐药)以及质粒DNA限制性图谱。这些分离株对头孢噻肟和克拉维酸(一种β-内酰胺酶抑制剂)的联合用药均敏感,二者表现出协同作用,提示存在β-内酰胺酶(头孢噻肟单独使用时几何平均最低抑菌浓度为11.24微克/毫升,与0.1微克/毫升克拉维酸钾联合使用时为0.24微克/毫升)。所有分离株都产生了TEM-1和SHV-2β-内酰胺酶,该酶不能通过接合作用转移至大肠杆菌。维也纳沙门氏菌中存在SHV-2酶可能使其能够适应更新型的β-内酰胺类药物,这在该医院是一个令人担忧的问题。